Telehealth General Psychiatry Prescribing: What Prescribers Can Do in Texas

If you’re a psychiatrist or psychiatric nurse practitioner trying to make sense of prescribing regulations—especially for telehealth—you’ve landed in the right place. The rules governing what you can prescribe, how you can prescribe it, and whether you need physician oversight vary wildly by state and provider type. And if you’re practicing via telemedicine across multiple states? The complexity multiplies fast.

Let’s cut through the confusion. This guide covers exactly what psychiatrists and PMHNPs can prescribe in 2026, how telehealth has changed the game for controlled substance prescribing, and what the state-by-state differences mean for your practice—particularly in California, Texas, Florida, New York, Pennsylvania, and Illinois.

The Core Question: What Authority Do Psychiatrists Have?

Psychiatrists (MD/DO) have the broadest prescribing authority in mental health care. With a valid state medical license and DEA registration, you can prescribe any psychiatric medication—antidepressants, antipsychotics, mood stabilizers, benzodiazepines, stimulants for ADHD, buprenorphine for opioid use disorder—without restriction or supervision in all 50 states.

This includes Schedule II controlled substances like Adderall and Ritalin, which are often the center of regulatory concern. Your authority is independent: no collaborative agreements, no chart reviews, no physician oversight required.

Psychiatric Mental Health Nurse Practitioners (PMHNPs), on the other hand, face a patchwork of state regulations. In about half of U.S. states, experienced PMHNPs now have Full Practice Authority (FPA)—meaning they can diagnose, treat, and prescribe independently, just like psychiatrists. But in the other half, PMHNPs must work under physician supervision or collaboration, with varying degrees of restriction on what they can prescribe and how.

The gap between MD and NP authority creates real friction in telehealth practices, where you might be licensed in multiple states with completely different rules.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Telehealth Prescribing: The Federal Landscape

The biggest shift in psychiatric prescribing over the past few years has been telehealth flexibility for controlled substances. Historically, the Ryan Haight Act required an in-person medical evaluation before prescribing any controlled substance. For psychiatry—where many core medications are Schedule II–V—that was a major barrier to telehealth.

Since March 2020, the DEA has waived the in-person exam requirement under public health emergency powers. As of early 2026, that waiver remains in effect through at least December 31, 2025, meaning psychiatrists can initiate controlled substance prescriptions (including stimulants, benzodiazepines, and buprenorphine) via telehealth to new patients without ever seeing them in person.

This is huge for psychiatric access. A patient in rural Texas with ADHD can now have a video visit with a psychiatrist and walk away with a prescription for Vyvanse—something that would have required an in-person visit pre-2020.

But there’s a catch: The DEA has proposed new permanent rules that could reimpose some restrictions. Proposed regulations include requiring special DEA telemedicine registration, limiting initial telehealth prescriptions to 30-day supplies, or requiring an in-person referral from another provider. The final rules were expected by late 2024 but have been repeatedly delayed. Psychiatrists should monitor DEA announcements closely—what’s allowed today may tighten tomorrow.

State-Level Telehealth Rules: Not All States Align

Even with federal flexibility, state laws can impose additional restrictions. Some states explicitly permit telehealth prescribing of controlled substances for psychiatric treatment; others have carved out exceptions or maintain stricter rules.

Florida, for example, has one of the most permissive statutes: state law explicitly allows controlled substances to be prescribed via telehealth for the treatment of psychiatric disorders (Florida Statutes 456.47). This means a Florida-licensed psychiatrist can prescribe ADHD stimulants or anti-anxiety medications to a Florida patient via video visit without issue. The only prohibition is for chronic non-malignant pain management, which still requires an in-person exam.

Texas also allows telehealth prescribing of controlled substances for mental health treatment, but prohibits tele-prescribing Schedule II opioids for chronic pain. Practically, a Texas psychiatrist can manage ADHD with stimulants via telehealth (not considered ‘chronic pain’), but must comply with strict telemedicine standards—including mandatory checks of the Texas Prescription Monitoring Program (PMP) before prescribing any controlled substance.

New York recently updated its rules (finalized in mid-2025) to explicitly align state law with federal DEA allowances. New York had technically required in-person exams for controlled substances under state regulation, but the new rule permits telehealth prescribing when federal law allows it—meaning as long as the DEA waiver is active, NY psychiatrists can prescribe controlled meds remotely. New York also has one future wrinkle: Medicare patients receiving tele-mental health services will eventually need an in-person visit at least once every 12 months (though this requirement has been repeatedly delayed).

California has no state-level prohibition on telehealth prescribing of controlled substances. California law requires a ‘good faith exam’ before prescribing, but explicitly recognizes video telehealth consultations as meeting that standard. During the federal waiver period, California psychiatrists have been initiating controlled meds via telemedicine routinely. You must check CURES (California’s prescription monitoring database) before prescribing Schedule II–IV drugs—this applies equally to telehealth and in-person practice.

Pennsylvania and Illinois largely defer to federal law on controlled substance telehealth prescribing. Both states support telehealth for mental health (Illinois even mandates insurance reimbursement parity through 2027), and neither has enacted specific state-level bans on tele-prescribing psychiatric controlled meds during the federal waiver period.

PMHNP vs. Psychiatrist: The Prescribing Authority Gap

Here’s where things get complicated if you’re a psychiatric nurse practitioner. Your prescribing authority—and whether you even need a physician collaborator—depends entirely on your state.

Full Practice Authority States (FPA)

In FPA states, PMHNPs can practice independently: assess patients, diagnose, and prescribe medications (including controlled substances) under their own license and DEA registration. No physician supervision required.

As of 2025, about 34 states plus DC grant NPs full practice authority. This includes states like Washington, Oregon, Arizona, New Mexico, Colorado, Montana, and recently Massachusetts, Kansas, Indiana, and Louisiana.

Among our priority states:

• New York is effectively FPA for experienced NPs. After accumulating 3,600 hours of supervised practice (roughly 2 years), a PMHNP can practice independently without a written collaborative agreement. They must attest to having informal ‘collaborative relationships’ with physicians for consultation, but there’s no formal supervision or chart review required.
• California is transitioning to FPA via a phased process under AB 890. Starting January 2023, NPs with ≥3 years of experience can become ‘103 NPs’ and practice without direct physician supervision in group settings. By January 2026, those NPs can apply to become ‘104 NPs’ and practice fully independently—including opening solo practices and prescribing without oversight. New graduate NPs still require physician-supervised standardized procedures for at least 3 years.
• Illinois allows NPs to achieve FPA after completing 4,000 hours of collaborative practice (about 2 years) plus 250 hours of continuing education in advanced pharmacology. Once the Illinois Department of Financial and Professional Regulation grants FPA licensure, PMHNPs can prescribe all psychiatric medications independently, including controlled substances.

Restricted and Reduced Practice States

The other half of states still require PMHNPs to work under some level of physician supervision or collaboration:

Texas is a restricted practice state. PMHNPs must have a written Prescriptive Authority Agreement with a Texas physician to prescribe any medication. The physician must be available for consultation, and the agreement must include a supervision plan—monthly face-to-face meetings for the first 3 years, then quarterly thereafter. Texas also limits one physician to supervising no more than 7 NPs/PAs at a time.

Critically, Texas law prohibits NPs from prescribing Schedule II controlled substances in outpatient settings except in very limited cases (terminally ill patients, emergencies). This means a Texas PMHNP generally cannot initiate ADHD stimulants independently—many work around this by having their supervising psychiatrist write initial Schedule II prescriptions, then the NP manages refills of Schedule III–V medications.

Florida is similarly restrictive for psychiatric NPs. While Florida passed a law (HB 607 in 2020) allowing some NPs to practice autonomously, psychiatric NPs were explicitly excluded. PMHNPs in Florida must practice under a supervising physician’s protocol.

However, Florida does provide a carve-out for prescribing: NPs certified as ‘psychiatric nurses’ (PMHNP with ≥2 years post-grad psych experience under a psychiatrist) can prescribe psychotropic controlled substances for mental health treatment in collaboration with a psychiatrist—without the 7-day supply limit that applies to other NP prescribing of Schedule II drugs.

Pennsylvania requires all NPs to maintain a collaborative agreement with a physician indefinitely. There is no pathway to independence as of 2026 (though legislation has been introduced). PA PMHNPs can prescribe Schedule II–V controlled substances if the collaborating physician delegates it, but Schedule II prescriptions are limited to 30-day supplies and the physician must be notified within 24 hours.

The Practical Impact

For telehealth platforms and multistate practices, these differences create operational complexity. A PMHNP licensed in both New York (FPA after 3,600 hours) and Texas (restricted) can practice independently when seeing NY patients but must have a collaborating physician and cannot prescribe stimulants when seeing Texas patients.

This is why many telehealth companies structure their provider teams with both psychiatrists and PMHNPs—psychiatrists handle patients in restrictive states or complex medication regimens, while experienced NPs in FPA states operate independently.

It also affects compensation models: Medicare reimburses NPs at 85% of physician rates when billing under the NP’s own NPI. Some private insurers follow similar structures, meaning an NP might generate less revenue per visit than a psychiatrist for the same work—even in states where their legal authority is identical.

Collaborative Agreements: What PMHNPs Need to Know

If you’re a PMHNP in a state that requires physician collaboration, understanding what goes into that agreement is critical for compliance and practice sustainability.

A collaborative practice agreement (CPA) typically includes:

Scope definition: Which conditions you can treat, which medications you can prescribe (including specific controlled substance schedules), and any exclusions. For example, an agreement might authorize prescribing for adults only, or exclude certain high-risk medications.

Physician availability: Requirements for how quickly your collaborating physician must respond to consultations, backup coverage when they’re unavailable, and frequency of meetings (monthly, quarterly, etc.).

Chart review protocols: Many states mandate the physician review a percentage of your charts regularly. South Carolina requires 10% monthly chart reviews; Tennessee requires periodic on-site visits. Texas doesn’t specify a percentage but requires documented quality assurance meetings where cases are reviewed.

Prescription limitations: Even if state law permits NP prescribing of certain drugs, your collaborating physician can impose narrower restrictions in the agreement. Common limitations include requiring physician approval for initial stimulant prescriptions, excluding prescribing for patients under 18, or requiring consultation for doses above certain thresholds.

State board filing: Some states (like Kentucky) require filing the CPA with the state board of nursing. Others don’t require filing but mandate the agreement be available on request during audits.

One major pain point for PMHNPs in restricted states: finding a collaborating psychiatrist. States like Florida and Pennsylvania require the collaborator be in the same specialty for psychiatric prescribing, and many psychiatrists charge substantial fees ($2,000–$5,000+ annually) to serve as collaborators—especially for remote arrangements. In underserved areas where psychiatrists are scarce, this requirement can delay or prevent PMHNPs from practicing.

For telehealth practices, collaborative agreements must also address multistate issues. If you’re seeing patients in multiple states, you may need separate agreements that comply with each state’s specific requirements—and those agreements must be updated if you change practice sites or if your collaborating physician moves.

Reimbursement: What Med Management Pays

Understanding reimbursement is crucial for practice sustainability, especially in telehealth where you’re weighing patient volume against per-visit economics.

Common Billing Codes

Psychiatrists typically bill medication management visits using Evaluation and Management (E/M) codes:

• CPT 90792 – Psychiatric diagnostic evaluation with medical services (initial ~60 min visit). Medicare 2026: ~$173
• CPT 99213 – Established patient office visit, 15–20 minutes, straightforward to moderate complexity. Medicare 2026: ~$95
• CPT 99214 – Established patient office visit, 25–30 minutes, moderate to high complexity. Medicare 2026: ~$136
• CPT 99215 – Established patient office visit, 40+ minutes, high complexity. Medicare 2026: ~$192

For brief medication checks (15 minutes reviewing adherence, side effects, minor dose adjustments), 99213 is most common. Longer or more complex visits (starting new medications, managing multiple conditions, crisis intervention) justify 99214.

If you’re combining medication management with psychotherapy in the same visit, you can bill the E/M code plus a psychotherapy add-on (90833 for 16–37 min, 90836 for 38–52 min, 90838 for 53+ min)—though pure med management visits are typically shorter and billed without add-ons.

Telehealth Payment Parity

One of the biggest wins for telepsychiatry has been payment parity: Medicare and most private insurers now reimburse telehealth mental health visits at the same rate as in-person visits.

Medicare has permanently allowed telehealth for mental health services (with a technical requirement for one in-person visit every 12 months that’s currently paused through 2025). You bill the same E/M codes for video visits using place of service code 02 or modifier -95.

Many states have enacted private insurance telehealth parity laws:

• Illinois mandates equal reimbursement for telehealth behavioral health through at least 2027
• California requires payment parity for telehealth services under contracts issued after 2021
• New York updated its law in 2021 to ensure telehealth coverage, with most insurers paying equal rates for tele-mental health
• Texas requires coverage but doesn’t mandate payment parity—though most major insurers voluntarily pay equal rates given provider demand

PMHNP vs. MD Reimbursement

Medicare reimburses nurse practitioners at 85% of physician rates when billing under the NP’s own NPI. So a 99213 that pays a psychiatrist $95 would pay a PMHNP about $81.

Many private insurers follow similar structures, though some states have passed ‘equal reimbursement’ laws requiring insurers pay NPs the same as physicians for identical services (Nevada, Maryland, and others).

For practice economics, this creates an interesting dynamic: even in FPA states where PMHNPs have identical legal authority to prescribe, they may generate less revenue per visit. Some practices work around this through ‘incident-to’ billing (billing the NP’s service under a supervising physician when done in the same office), but incident-to billing doesn’t apply to telehealth services under current Medicare rules.

Medicaid and Cash Pay

Medicaid rates vary widely by state but tend to be lower than Medicare. Florida Medicaid might pay $60–$80 for a brief med check; California Medi-Cal historically paid about 75% of Medicare rates (though recent investments aim to increase behavioral health reimbursement).

Many psychiatrists—especially in high-demand specialties like ADHD treatment—operate cash-pay or out-of-network to avoid low reimbursement and administrative burden. Cash rates for 15-minute med checks typically range $100–$200 depending on market and specialty.

For telehealth platforms, the economics often favor a mixed model: accept insurance for broader access, but structure provider compensation to account for reimbursement differences between MDs and NPs, and between payers.

State-by-State Breakdown: Where the Rules Differ Most

Let’s break down prescribing authority and telehealth rules in the six priority states where differences matter most for psychiatric practice:

California: Transitioning to Full NP Independence

Psychiatrists: Full independent prescribing authority. No restrictions on telehealth controlled substance prescribing (aside from federal DEA rules). Must check CURES database before prescribing Schedule II–IV.

PMHNPs: Currently in transition under AB 890. New graduate NPs must work under physician-supervised standardized procedures. After 3 years of experience, NPs can become ‘103 NPs’ (practice without direct supervision in group settings). By January 2026, experienced NPs can become ‘104 NPs’ and practice fully independently—including solo practice and unrestricted prescribing.

Market reality: California faces massive mental health workforce shortages—11+ million Californians live in mental health professional shortage areas. The AB 890 pathway is specifically designed to expand PMHNP capacity in underserved regions. By 2026, California will effectively be a full practice state for experienced psychiatric NPs.

Texas: Strict Supervision Requirements

Psychiatrists: Full independent prescribing. Telehealth prescribing allowed for mental health treatment, including controlled substances (but not Schedule II opioids for chronic pain).

PMHNPs: Must maintain Prescriptive Authority Agreement with Texas physician indefinitely—no pathway to independence. NPs cannot prescribe Schedule II controlled substances in outpatient settings except narrow exceptions. Physician limited to supervising 7 NPs maximum; monthly meetings required for first 3 years, then quarterly.

Market reality: Texas has one of the worst psychiatrist-to-population ratios nationally (~1:8,500 residents), with 380 mental health shortage areas needing 614 additional psychiatrists. Despite high demand, restrictive NP scope laws limit workforce expansion. Many PMHNPs work in settings where the employing group provides collaborating physicians.

Florida: Psych NPs Excluded from Autonomy

Psychiatrists: Full independent prescribing. Florida explicitly permits telehealth prescribing of controlled substances for psychiatric treatment—one of the most permissive state laws.

PMHNPs: Excluded from Florida’s autonomous APRN pathway (which applies only to primary care NPs). Must practice under physician protocol. However, certified ‘psychiatric nurses’ (PMHNP with 2+ years psych experience under a psychiatrist) can prescribe psychotropic controlled substances in collaboration with a psychiatrist without the 7-day Schedule II supply limit that applies to other NPs.

Market reality: Florida has severe psychiatrist shortages (~1:9,000 residents) and 7.8 million residents in mental health shortage areas. Bills to extend autonomous practice to psychiatric NPs have been introduced but not passed as of 2025.

New York: Independence After 3,600 Hours

Psychiatrists: Full independent prescribing. NY recently finalized rules aligning state controlled substance teleprescribing with federal DEA allowances.

PMHNPs: Must initially practice under written collaborative agreement with physician for first 3,600 hours (~2 years). After reaching 3,600 hours, can practice independently with only informal ‘collaborative relationship’ requirement (no supervision, chart review, or formal oversight). Effectively full practice authority for experienced NPs.

Market reality: New York has high psychiatrist concentration in NYC (~1:2,900 statewide), but upstate regions face severe shortages. The 2022 law making NP independence permanent was specifically aimed at expanding access in underserved areas. Many experienced PMHNPs now run independent practices upstate.

Pennsylvania: Ongoing Collaboration Required

Psychiatrists: Full independent prescribing. PA supports telehealth for mental health; no unique state restrictions on controlled substance tele-prescribing beyond federal law.

PMHNPs: Must maintain collaborative agreement with physician indefinitely. No pathway to independence as of 2026 (legislation introduced but not passed). Can prescribe Schedule II–V if delegated, but Schedule II limited to 30-day supplies with physician notification within 24 hours. Physician must review portion of charts regularly.

Market reality: Pennsylvania has mid-range psychiatrist density (~1:4,600) but significant rural shortages. Neighboring states (NY, Ohio) have moved to full practice authority, creating pressure on PA to follow suit. Many expect FPA legislation within 2–3 years.

Illinois: Transition to Full Authority After Experience

Psychiatrists: Full independent prescribing. Illinois has strong telehealth parity—insurance must reimburse tele-mental health equally through 2027.

PMHNPs: Must practice under Written Collaborative Agreement initially. After completing 4,000 hours collaborative practice + 250 hours continuing education in pharmacology, can apply for Full Practice Authority license. With FPA, can prescribe all psychiatric medications independently including controlled substances.

Market reality: Illinois has ~291 practitioners needed to eliminate mental health shortages. The FPA pathway (effective 2018) has gradually expanded independent NP practice. Illinois also uniquely allows specially trained clinical psychologists to prescribe limited mental health medications under psychiatrist supervision—another effort to address shortages.

The Economics of Patient Acquisition for Psychiatrists

Let’s talk about the real cost of building a patient panel—because this is where platforms like Klarity Health fundamentally change the game.

The Reality of DIY Marketing

If you’re trying to acquire psychiatric patients through traditional marketing, here’s what you’re actually up against:

SEO takes 6–12 months of consistent investment before generating meaningful patient flow. You need a professional website, ongoing content creation, technical optimization, and backlink building. Budget: $2,000–$5,000/month for a competent agency, with no guaranteed results for at least half a year.

Google Ads for mental health keywords run $15–$40+ per click. Most clicks don’t convert to booked patients—maybe 5–10% if you’re lucky and your landing pages are optimized. Factor in ad spend testing, optimization time, and staff hours to field and qualify leads, and you’re looking at $200–$400+ per actual booked patient.

Directory listings (Psychology Today, Zocdoc) charge monthly subscription fees ($30–$100/month) plus per-booking fees ($35–$100 per new patient on Zocdoc). You’re competing with hundreds of other providers on the same page. Conversion rates are unpredictable.

Total realistic patient acquisition cost through DIY marketing: $200–$500+ per qualified patient when you factor in ALL costs—agency fees, ad spend, staff time handling leads, no-shows from cold leads, months of investment before results, failed campaigns, and opportunity cost of your time managing all this instead of seeing patients.

And that’s assuming you have the expertise (or pay for the expertise) to do it right. Most solo psychiatrists don’t.

The Klarity Health Alternative

Klarity uses a pay-per-appointment model where you pay a standard listing fee per new patient lead. That’s it. No upfront marketing spend. No monthly subscription hoping for results. No wasted ad budget on clicks that don’t convert.

The economics are straightforward:

• No gambling on marketing channels with uncertain ROI
• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

Compare that to spending $3,000–$5,000/month on marketing with no guarantee you’ll book enough patients to break even. With Klarity, you’re paying only for patients who actually show up on your calendar—guaranteed ROI instead of marketing risk.

For established psychiatrists looking to scale, this removes the biggest bottleneck. For PMHNPs starting out or navigating collaborative agreement requirements in restrictive states, it provides patient volume without the upfront capital investment and expertise required for DIY marketing.

What This Means for Your Practice

Whether you’re a psychiatrist with full prescribing authority or a PMHNP navigating collaborative agreements, the regulatory landscape for psychiatric prescribing is more favorable in 2026 than it’s ever been—especially for telehealth.

Federal telehealth waivers allow you to prescribe controlled substances remotely (for now). Most states support payment parity for tele-mental health. And the trend is clearly toward expanding PMHNP independence, with multiple states moving to full practice authority in recent years.

But the complexity remains real. You need to:

• Stay current on DEA rule changes that could affect controlled substance prescribing
• Understand your state’s specific scope of practice laws if you’re a PMHNP
• Maintain compliance with collaborative agreements in restricted states
• Check prescription monitoring databases before prescribing controlled meds
• Ensure your telehealth platform meets state requirements for patient exams
• Track reimbursement rules by payer and state

That’s a lot to manage on top of actually practicing psychiatry.

Platforms like Klarity Health handle the infrastructure—patient acquisition, telehealth technology, credentialing, and compliance frameworks—so you can focus on what you do best: managing medications and improving patient outcomes.

If you’re ready to expand your telehealth practice without gambling on expensive marketing or drowning in multistate compliance complexity, explore joining Klarity’s provider network. We handle patient acquisition, you handle clinical care, and both sides win.

FAQ: Psychiatric Prescribing Authority

Can psychiatrists prescribe controlled substances via telehealth in 2026?
Yes. Under current DEA waivers (extended through December 31, 2025), psychiatrists can prescribe Schedule II–V controlled substances via telehealth to new patients without an in-person exam. This includes stimulants for ADHD, benzodiazepines for anxiety, and buprenorphine for opioid use disorder. However, the DEA has proposed new permanent rules that may reimpose some restrictions—psychiatrists should monitor federal announcements for changes.

What’s the difference between PMHNP and psychiatrist prescribing authority?
Psychiatrists have full independent prescribing authority in all 50 states. PMHNPs’ authority depends on state law: in Full Practice Authority states (about half the U.S.), experienced PMHNPs can prescribe independently including controlled substances. In restricted states like Texas, Florida, and Pennsylvania, PMHNPs must work under physician supervision and face limitations on prescribing—particularly Schedule II controlled substances.

Which states allow PMHNPs to prescribe independently?
As of 2025, about 34 states plus DC grant full practice authority to NPs. Among major states: New York (after 3,600 hours), California (after 3 years, becoming fully independent in 2026), and Illinois (after 4,000 hours + continuing education) allow experienced PMHNPs to prescribe independently. Texas, Florida, and Pennsylvania still require ongoing physician collaboration.

Can I prescribe ADHD stimulants via telehealth?
Yes, if you’re a psychiatrist or a PMHNP with appropriate authority in your state. Under current federal waivers, you can initiate stimulant prescriptions (Schedule II) via video visit without an in-person exam. Some states have specific rules: Texas allows it for mental health treatment but restricts certain pain management prescribing; Florida explicitly permits it for psychiatric disorders. Check your state’s prescription monitoring program requirements—most states mandate checking the database before prescribing Schedule II.

How much does Medicare pay for psychiatric medication management visits?
Medicare 2026 rates: approximately $173 for an initial psychiatric evaluation (90792), $95 for a 15-minute follow-up med check (99213), and $136 for a 25-minute follow-up (99214). Telehealth visits are reimbursed at the same rate as in-person visits for mental health services. PMHNPs are reimbursed at 85% of physician rates when billing under their own NPI.

Do I need a collaborative agreement to prescribe as a PMHNP?
It depends on your state. In Full Practice Authority states, experienced PMHNPs can prescribe without a collaborative agreement. In restricted states (Texas, Florida, Pennsylvania), you must maintain a written collaborative agreement with a physician that defines your prescribing authority, includes chart review protocols, and specifies which medications you can prescribe. Some states require filing the agreement with the state board of nursing.

What’s the real cost of acquiring new psychiatric patients through marketing?
When you factor in all costs—SEO agency fees ($2,000–$5,000/month), Google Ads spend ($15–$40/click with low conversion), directory subscriptions, staff time qualifying leads, and months of investment before results—realistic patient acquisition cost is $200–$500+ per booked patient. Platforms using pay-per-appointment models eliminate this upfront risk by charging only when qualified patients actually book with you.

Can PMHNPs prescribe buprenorphine for opioid use disorder?
In Full Practice Authority states, yes—PMHNPs with DEA registration can prescribe buprenorphine independently (the federal X-waiver requirement was eliminated in 2023). In restricted states, PMHNPs can prescribe buprenorphine if it’s explicitly delegated in their collaborative agreement with a physician. Some states classify buprenorphine as Schedule III, making it more accessible than Schedule II stimulants for NP prescribing.

Sources and References

Source:

• https://www.bon.texas.gov/faq_practice_aprn.asp.html
• https://www.npschools.com/blog/guide-to-np-practice-in-florida
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era
• https://www.flsenate.gov/laws/statutes/2024/464.012
• https://www.cchpca.org/texas/
• https://www.nursepractitioneronline.com/articles/nurse-practitioner-practice-authority-updates/
• https://www.pacnp.org/general/custom.asp?page=ScopeofPractice
• https://www.jdsupra.com/legalnews/new-law-allows-experienced-nps-to-8292796/